ABBV vs VRT: Which Is the Better Buy?

Side-by-side comparison of AbbVie Inc. and Vertiv Holdings Co — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C High Quality
VS
Vertiv Holdings Co · Industrials
$333.05
-45.0% upside to fair value
Grade D High Quality
QuantHub Verdict
ABBV has more upside to fair value (+1.2%). VRT trades at a lower forward P/E (81.8x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric ABBV VRT
Current Price $261.07 $333.05
Fair Value Estimate $264.30 $183.18
Upside to Fair Value +1.2% -45.0%
Market Cap $461.3B $127.9B
Forward P/E 128.0x 81.8x
EV / EBITDA 31.0x 55.4x
Price / Sales 7.3x 11.8x
Price / FCF 22.1x 55.4x
Revenue Growth YoY +12.4% +30.1%
Gross Margin 70.7% 36.2%
Operating Margin 27.6% 18.5%
Return on Equity 68.0% 42.1%
Dividend Yield 0% 0%
FCF Yield 4.52% 1.81%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
ABBV — AbbVie Inc.
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
VRT — Vertiv Holdings Co
Vertiv Holdings Co operates in the industrials sector, specializing in electrical equipment and parts with a strong focus on data center critical infrastructure. The company benefits from a durable competitive position supported by a broad product portfolio that drives approximately 75% of sales from data centers. Vertiv's business quality is high, demonstrated by a 42.1% return on equity, strong…
Accumulation Zones
Metric ABBV VRT
Zone Low $198.23 $137.38
Zone High $224.66 $155.70
In Buy Zone? No No
← ABBV Research    VRT Research →    All Research